Anti glioma effect of doxorubicin loaded liposomes modified with angiopep-2 | Zendy

Mei Danyu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti glioma effect of doxorubicin loaded liposomes modified with angiopep-2

Author(s) -

Mei Danyu

Publication year - 2011

Publication title -

african journal of pharmacy and pharmacology

Language(s) - English

Resource type - Journals

ISSN - 1996-0816

DOI - 10.5897/ajpp11.068

Subject(s) - glioma , liposome , doxorubicin , chemistry , drug delivery , apoptosis , brain tumor , pharmacology , cancer research , targeted drug delivery , chemotherapy , medicine , drug , pathology , biochemistry , organic chemistry

The low-density lipoprotein receptor-related protein (LRP) was highly expressed in blood brain barrier and glioma cells. Angiopep-2 was a new and effective ligand of LRP. Herein, we present a novel brain targeting delivery system: doxorubicin (DOX) loaded angiopep-2 modified liposome (AL). The particle size of AL was 102 nm and the zeta potential was -9.8 mV, which was stable and suitable for brain targeting delivery. In the anti glioma study, AL group had the smallest average tumor volume, the strongest tumor apoptosis, gain more weight after treatment and longer median survival time than that of other groups. This proved that Angiopep-2 modified doxorubicin liposomes had certain glioma targeting therapeutic effects and lower toxicity. Key words: Angiopep-2, liposome, glioma, targeted drug delivery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research